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ABSTRACT 
Development of a Novel Diagnostic Test Using Podocyturia as a Biomarker for Detection of 
Kidney Damage. (May 2013) 
 
 
Eesha Farooqi 
Department of 
Veterinary Medicine 
Texas A&M University 
 
 
Research Advisor: Dr. Mary Nabity 
Department of  
Veterinary Pathobiology 
 
 
Primary glomerular diseases are the most common cause of progressive chronic kidney disease 
(CKD) in dogs, a common and significant source of illness that often progresses to kidney 
failure. It is hypothesized that podocyte cells in the glomerulus are washed away in urine as a 
result of glomerular damage. Using markers such as podocyte gene products, more sensitive and 
specific detection of damage to the glomeruli is possible, allowing for earlier treatment of CKD 
that could potentially prolong the life of dogs. The purpose of this study was to develop novel 
non-invasive markers of CKD, specifically podocyturia, and optimize primer and probe sets that 
could be used on urine sediment to detect podocyte gene products effectively and efficiently. 
Primer-probe sets were developed for both reference genes and podocyte gene products. Primer 
concentrations were optimized and both reference genes and podocyte genes amplified 
efficiently under optimal concentrations in kidney tissue. 
With additional testing using urine sediment, analysis and statistical correlation between 
podocyte loss and glomerular damage may be able to provide insight into the pathogenesis and 
treatment of CKD in dogs. 
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CHAPTER I 
INTRODUCTION 
 
Primary glomerular diseases are a leading cause of chronic kidney disease (CKD) in both 
humans and animals. These disorders are characterized by abnormal structure and function of the 
glomerulus, a key compartment of the functional unit of the kidney, the nephron. Blood that 
travels through the kidney is filtered at the glomerulus. The rate of this filtration, and thus 
measure of overall kidney function, is the glomerular filtration rate (GFR). 
 
Damage to the glomerulus therefore is a good measure of kidney dysfunction (Bostom et al, 
2002). Such damage invariably leads to protein loss, known as proteinuria, and might possibly 
result in cell sediment shedding. Intermediate to high molecular weight proteins such as albumin, 
if found in urine and not caused by pre- or post-renal factors, are indicative of kidney damage. 
Additionally, special glomerular cells, known as podocytes, are also thought to be markers of 
glomerular damage if found in urine (Petermann and Floege, 2007). Podocytes overlie the 
glomerular basement membrane (GBM), and along with the GBM and endothelium, the 
podocyte layer comprises one of the three main components of the glomerular filtration barrier. 
 
While evidence of kidney damage is common, progressive CKD is not recognized as frequently 
due to the insidious nature of the disease and the lack of sensitive and specific non-invasive 
diagnostic tests (Petermann and Floege, 2007).  Although the magnitude of proteinuria has 
prognostic significance in dogs, proteinuria can be indicative of either ongoing or previous injury 
(Jacob et. al., 2005). Podocyturia, on the other hand, is thought to indicate active glomerular 
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injury, and it might therefore determine whether treatment for glomerular disease is effective and 
whether the disease is likely to progress (Schmid et. al., 2003). Therefore, measuring cell content 
in urine can indicate active glomerular injury, and may possibly provide a novel, non-invasive 
test for determining progression of CKD in dogs. 
 
The main objective of this study was to develop a novel, non-invasive method to detect podocyte 
injury in dogs. In particular, we designed primers and probes to amplify RNA isolated from urine 
sediment in for the detection of podocyturia. These biomarkers will eventually be evaluated for 
their reliability in detecting glomerular injury and determining CKD progression. In addition to 
these experimental tests, we conducted surveys which were sent to the patients’ owner or 
attending clinician, in order to assess the long-term outcome of each dog and determine the 
clinical value of both novel and conventional tests of kidney function and damage. 
 
The central hypothesis is that detection of podocyte gene expression profiles in urine will 
improve detection of glomerular injury and will correlate better with the severity of glomerular 
damage and prognosis in dogs with CKD than traditional diagnostic tests such as proteinuria. In 
order to develop a test for podocyturia, we had two main objectives: 
 
1) Determine which reference genes to use as a baseline for accurately measuring podocyturia 
 Design sequences for primer-probe sets. 
 Verify specific amplification of desired gene using RT-PCR. 
 Optimize concentrations of primer-probe sets. 
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 Perform quantitative RT-PCR (qRT-PCR) on mRNA isolated from banked kidney 
tissue and a variety of urine sediments from dogs. 
 
2) Develop canine-specific primer-probe sets to be used in detecting podocyte gene products 
(podocin, nephrin, and actinin-4). 
 Similarly design, verify, optimize, and perform qRT-PCR on isolated mRNA to 
detect podocyte gene products. 
 
Once all primer-probes are optimized and demonstrate amplification using kidney tissue and 
urine sediment, the correlation of podocyturia and glomerular damage will be performed to 
determine its diagnostic value in comparison to traditional methods such as the urine 
protein:creatinine ratio (UPC).  
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CHAPTER II 
METHODS 
 
Collection of kidney tissue and urine sediment 
Banked kidney tissue was previously obtained post-euthanasia from dogs affected with X-linked 
hereditary nephropathy (XLHN) after they reached end-stage CKD. Tissue was cut into 0.5-1 cm 
fragments, placed in RNAlater, and stored at either 4
o
C or -80
o
C until processing. Voided urine 
samples (~5-10 ml) were also collected from dogs with XLHN and centrifuged at 500xg for 10 
min, allowing any cell sediment to form a pellet at the bottom of the tube. Urine supernatant was 
carefully removed, to avoid disturbing the sediment pellet. Next, the sediment was resuspended 
in 1 ml RNAlater to stabilize the RNA, and the samples were either stored at either 4
o
C or -80
o
C 
until RNA isolation.  
 
Isolation of RNA from kidney tissue and urine sediment and conversion to cDNA 
For urine sediment, we used TRI Zol (Sigma TRI Reagent) to isolate RNA from urine sediment, 
using two chloroform separation steps to increase RNA quality as described below. First, the 
urine sediment suspended in RNAlater was centrifuged to pellet any cellular material. The 
supernatant was removed and the sediment was lysed with 750 ulTRI Reagent by repeated 
pipetting. Samples were incubated for 5 minutes at room temperature and then 150 ul of 
chloroform was added. The sample was covered tightly, shaken vigorously for 15 seconds, and 
incubated for 2–3 minutes at room temperature. The resulting mixture was centrifuged at 12,000 
x´ g for 15 minutes at 4 °C. Centrifugation separated the mixture into 3 phases: a red organic 
phase (containing protein), an interphase (containing DNA), and a colorless upper aqueous phase 
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(containing RNA). Using the aqueous phase, the chloroform step was repeated once. Next, the 
aqueous phase was transferred to a fresh tube followed b addition of 400 ul isopropanol. The 
sample was incubated for 10 minutes at room temperature then centrifuged at 12,000 x´ g for 10 
minutes at 4 °C. The RNA precipitate formed a pellet on the side and bottom of the tube. The 
supernatant was removed and the RNA pellet was washed by adding 750ul of 75% ethanol. The 
sample was vortexed briefly and then centrifuged at 7,500 x g for 5 minutes at 4°C. Lastly, the 
RNA pellet was air dried for 5–10 minutes, taking care not to let the RNA pellet dry completely. 
The RNA pellet was resuspended in 10ul RNase-free water. To facilitate dissolution, repeated 
pipetting with a micropipette at 55–60 °C for 10–15 minutes was performed. RNA isolated from 
kidney tissue and urine sediment was reverse transcribed into cDNA using Quantitect 's Reverse 
Transcription Kit. RNA samples and kit contents were bought to room temperature. To eliminate 
genomic DNA, 4ul gDNA wipeout buffer and 23ul DNase-free water were added to each 1ul of 
RNA. Samples were incubated for 2 minutes at 42°C and placed on ice. RNA then was reverse 
transcribed into cDNA by adding 2ul RT enzyme, 2ul of a primer mix, and 8ul RT 5x buffer to 
the samples and incubated for 15 minutes at 42°C. The RT enzyme was inactivated by heating 
the samples for 3 minutes at 95°C. RNA and cDNA was stored at -20°C. 
 
Primer-probe design and verification: reference genes & podocyte genes 
Design of primers and probes 
In order to more accurately quantify the presence of podocyturia among samples, appropriate 
reference genes were needed that showed stable, non-fluctuating levels in both normal and 
abnormal kidney tissue and urine sediment in dogs. Tested genes included Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), 40S ribosomal protein S18 (RPS-18), ribosomal protein 
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L32 (RPL-32), beta actin (ACTB) and glucuronidase beta (GUSB-1). Primers and probes were 
either proprietary (ordered from a company, e.g., RPS18, RPL32), obtained from the literature 
(e.g, GAPDH, GUSB), or designed using Primer3 software (e.g ACTB.). Canine-specific 
primers for podocyte gene products, (nephrin, podocin, and actinin-4) were obtained from 
previously published sequences (Kobayashi 2011) or were designed using Primer3software. All 
probes were designed using Primer3. 
 
Verification of primer specificity 
Primer sets were validated by performing simple PCR reactions using cDNA from canine kidney 
tissue, visualizing the PCR products on a 1.5% agarose gel, and then sequencing the PCR 
products. BLAST online software was used to confirm that the product matched similar 
published gene sequences for the target gene in the NCBI database. PCR reactions were 
performed using BioRad iCycler IQ. A PCR reaction mix was prepared as outlined in Table B1, 
Table A1. Gene Sequences for Primers and Probes 
Ref. Gene Forward Reverse Probe 
GUSB-1 GGTGCGTCGGGA
-TAAGAAT 
CCCAGGTCTGCTTCATAGTTG 6FAM-
CACTTCCTTCCTGAAGCCTG-BHQ 
GAPDH CGGATTTGGCCG-
TATTGG 
GACAATATCCACTTTGCCAGA-
GTTAA 
6FAM-CGCCTGGTCACCAGGGC-
BHQ 
RPS-18 Proprietary Proprietary Proprietary 
RPL-32 Proprietary Proprietary Proprietary 
B-actin CCAAAAGCACTCT
-TCCAACC 
GCACTGTGTTGGCATACAGG  
Pod. Gene Forward Reverse Probe 
Nephrin GGTGCGTCGGGA
-TAAGAAT 
CCCAGGTCTGCTTCATAGTTG 6FAM-
CACTTCCTTCCTGAAGCCTG-BHQ 
Podocin CGGATTTGGCCG-
TATTGG 
GACAATATCCACTTTGCCAGA-
GTTAA 
6FAM-CGCCTGGTCACCAGGGC-
BHQ 
Actinin-4 CAATGCACTGATC
-CACCGG 
 
TTCACGATGTCCTCCGCA 
 
6FAM-
CACAGACCAGAGCTGATCGA-
BHQ 
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preparing enough volume to run at least two replicates of each sample. All components were 
combined (on ice) except the sample cDNA. This master mix then was aliquoted into different 
tubes, followed by addition of the appropriate cDNA type and volume to each. Tubes were 
briefly centrifuged to ensure homogenization. The following thermal cycling conditions were 
used: polymerase activation and DNA denaturation for 2 min at 95oC once, then 40 cycles of 
denaturing for 15 sec at 95oC and annealing/extension for 30sec at 60oC. 
 
 
 
 
 
 
 
A 1% agarose gel was used to detect the amplified PCR product. First, the appropriate amount of 
agarose was calculated and measured. For example, for a small, 8-well gel, 0.5 g of agarose was 
added to 50ml of 1x TAE buffer, whereas for a 15 or 20-well gel, 1.0 g of agarose was added to 
100ml of 1x TAE buffer. The dry agarose was added to a 250ml flask followed by the 
appropriate volume of TAE, swirling to mix. The solution was microwaved in short increments 
and mixed frequently, taking care not to let the solution bubble over. The agarose dissolved 
completely, resulting in a transparent solution. Next, 2.5ul GelRed nucleic acid stain was added 
to the flask and immediately mixed to avoid clumping. The mixture was cooled to lukewarm 
(~15 minutes) then poured into the gel apparatus, pushing any air bubbles to the side with a fine 
tip. Once the gel solidified (~30 min to 1 hour), well were loaded with 10ul of a PCR reaction 
Table B1. Simple PCR Reaction Mix 
Reaction Component Volume (ul) per Sample 
SsoFast Probes Supermix (2X) 10.0 
Primer-probe mix 1.0 
cDNA sample 1.0 
Water 8.0 
Total 20.0 
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mixed with 1ul of 6x loading buffer. A 1kb+ ladder (5ul) was used to verify size of the PCR 
product. Gels were run at 90 V for 30 minutes, or until the dye front reached the end of the gel. 
 
Reverse transcriptase polymerase chain reaction (rt-pcr) and primer-probe optimization 
Both the reference genes and podocyte gene primer and probe sets were tested on cDNA from 
canine kidney cortex obtained from dogs with CKD due to XLHN to verify their performance 
using a two-step qRT-PCR reaction. In step one, RNA isolated from urine sediment was reverse 
transcribed into cDNA using Quantitect's Reverse Transcription Kit as described above. In step 
two, we analyzed gene expression using a BioRad CFX96 real-time PCR detection system. We 
prepared 20uL samples using the PCR reaction mix described in Table C1. We used the 
following PCR cycling protocol: initial denaturation 95oC for 2 min; and 40 cycles of 
denaturation 95oC for 15 sec, annealing/ extension 55oC for 30 sec. 
  
Once amplification and detection were confirmed, primer concentrations were optimized to 
obtain the most efficient results. A PCR reaction mix was prepared (shown in Table C1) to run 
four replicates of each of the nine conditions shown in Table D1. A 96-well PCR plate was 
loaded similar to the layout of Table D1, with four replicates for each sample. Wells were sealed 
with transparent film and the plate was centrifuged at 1200 xg for 5 min. The plate was placed in 
the qRT-PCR machine, and the thermal cycling conditions given above were followed. 
 
Probe concentration also was optimized for the reference genes following the same PCR reaction 
and thermal cycling steps above, with four replicates each of 50nM, 150nM, and 250nM 
concentrations using the optimal primer concentrations. 
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Table C1. PCR Reaction Mix 
Reaction Component Volume (ul) per Sample 
SsoFast Probes Supermix (2X) 10.0 
Primer-probe mix 1.0 
cDNA sample 1.0 
Water 8.0 
Total 20.0 
Table D1. Optimization of Primers and Probes 
 
Forward Primers 
Reverse  Primers 
50 300 900 
50 50/50 300/50 900/50 
300 50/300 300/300 900/300 
900 50/900 300/900 900/900 
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CHAPTER III 
RESULTS 
 
Reference gene optimization 
Results from PCR testing showed successful amplification of reference genes in kidney tissue for 
GUSB-1 (Ct.=30.0), GAPDH (Ct.=25.0), and RPS-18 (Ct=21.0). Two other reference genes, 
RPL-32 and beta-actin, amplified but had higher Ct. values, (34 and 32 respectively). These 
primer-probe sets appear to be specifically amplifying the desired gene product based on 
amplification of RNA isolated from kidney tissue.  
 
 
 
 
 
 
 
Fig. 1. 1.5% Agarose Gel of Reference and Podocyte Gene PCR Products 
Optimal probe concentration for all reference genes was 50nM/ul. Optimal concentrations for 
primers were available for GAPDH and GUSB-1: forward = 50nM/uL, reverse = 900nM/uL 
(GAPDH) and forward = 300nM/uL, reverse = 900nM/uL (GUSB-1).  
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Podocyte primer optimization 
After using different sequence variations for nephrin, podocin, and actinin-4 primers, nephrin 
and actinin-4 showed successful amplification in kidney tissue, with Ct values of 33 and 29, 
respectively. Optimal primer concentrations for nephrin were 900nM/uL forward and 300nM/uL 
reverse.  Optimal primer concentrations for actinin-4 were 50nM/uL forward and 300nM/uL 
reverse. Further testing is still in progress to determine whether amounts of these gene products 
fluctuate with progression of CKD. 
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CHAPTER IV 
CONCLUSIONS AND ANALYSIS 
 
Based on our findings, our hypothesis still holds true for the potential of using podocyte gene 
products found in urine as valuable markers in the diagnosis of Chronic Kidney Disease. RNA 
was successfully isolated from urine sediment and appropriate primer-probe sets were designed 
for multiple reference genes and podocyte-specific genes. These primer-probe sets were also 
optimized for qPCR with regard to primer-probe concentrations, and successful amplifications of 
targeted gene products show promising applications of these primer-probe sets. This sets a good 
foundation for future work in evaluating the usefulness of podocyturia in the detection and 
monitoring of CKD in dogs, and continued testing of these primers-probes on urine sediment 
may be able to provide a better scope and analysis of this novel diagnostic test. 
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